Trending

GlaxoSmithKline

AZ to continue with investment freeze following ‘no deal’ Brexit

AZ to continue with investment freeze following ‘no deal’ Brexit

AstraZeneca will keep manufacturing investments in Britain on hold if the UK’s negotiations with Brussels fail to provide

X

AZ to continue with investment freeze following ‘no deal’ Brexit

https://pharmaphorum.com/news/az-to-continue-with-investment-freeze-following-no-deal-brexit/

Digital health round-up: Pfizer appoints chief digital officer and more

Digital health round-up: Pfizer appoints chief digital officer and more

Pfizer has appointed a chief digital officer because of the growing importance of digital technology in its R&D

X

Digital health round-up: Pfizer appoints chief digital officer and more

https://pharmaphorum.com/views-and-analysis/digital-health-round-up-pfizer-appoints-chief-digital-officer-and-more/

Calls for ‘Sunshine Act’ as GSK pays doctors to promote drugs again

Calls for ‘Sunshine Act’ as GSK pays doctors to promote drugs again

GlaxoSmithKline (GSK) will pay some doctors for promoting its drugs reversing its previous policy, sparking new calls for

X

Calls for ‘Sunshine Act’ as GSK pays doctors to promote drugs again

https://pharmaphorum.com/news/calls-for-sunshine-act-as-gsk-pays-doctors-to-promote-drugs-again/

GSK TB vaccine shows promise, but more trials needed

GSK TB vaccine shows promise, but more trials needed

GlaxoSmithKline’s experimental TB vaccine has shown that it could help prevent the disease, but further research is needed

X

GSK TB vaccine shows promise, but more trials needed

https://pharmaphorum.com/news/gsk-tb-vaccine-shows-promise-but-more-trials-needed/

GSK cuts 650 jobs in the US

GSK cuts 650 jobs in the US

GlaxoSmithKline moves ahead with its planed cost saving strategy and cuts 650 jobs in North Carolina, according to

X

GSK cuts 650 jobs in the US

https://pharmaphorum.com/news/glaxosmithkline-cuts-650-jobs/

AZ’s lupus drug fails in late-stage trial

AZ’s lupus drug fails in late-stage trial

AZ will launch full review after further phase 3 results later this year

X

AZ’s lupus drug fails in late-stage trial

https://pharmaphorum.com/news/astrazeneca-anifrolumab-fails-trial/

AZ COPD drug fails to match GSK rival after disappointing launch

AZ COPD drug fails to match GSK rival after disappointing launch

AstraZeneca has said it is analysing “inconsistent” results after a late-stage trial of its Bevespi Aerosphere inhaler in

X

AZ COPD drug fails to match GSK rival after disappointing launch

https://pharmaphorum.com/news/az-copd-drug-fails-match-gsk-rival/

GSK’s Indian Horlicks sale may fetch over $4 billion

GSK’s Indian Horlicks sale may fetch over $4 billion

GlaxoSmithKline (GSK) has accelerated the review of its Horlicks business in India, hoping to sell it for over

X

GSK’s Indian Horlicks sale may fetch over $4 billion

https://pharmaphorum.com/news/gsk-indian-horlicks-sell-might-fetch-4-billion/

GSK’s monthly HIV treatment breakthrough

GSK’s monthly HIV treatment breakthrough

GlaxoSmithKline has seen positive clinical results from the phase 3 study of its once-monthly injectable HIV treatment, stepping

X

GSK’s monthly HIV treatment breakthrough

https://pharmaphorum.com/news/gsks-monthly-hiv-treatment-breakthrough/

1 2 3 4 5 >»

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com